Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2026 Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026 Management changes: Anton Hansson starts as CFO, while Julie Waras Brogren leaves her position as Deputy CEO KEY EVENTS AFTER THE PERIOD Ascelia Pharma completes directed share issue of SEK 20 million before transaction costs FINANCIAL SUMMARY Q1 (Jan-Mar) 2026 Operating result of SEK -17.2M (SEK -20.3M) Earnings per share of SEK -0.13 (SEK -0.23) Cash flow from operations of SEK -15.9M (SEK -16.9M) Liquid assets and marketable securities of SEK 33.9M (SEK 57.3M) "Orviglance® is on track for approval on the July 3 PDUFA date. FDA's review of our New Drug Application (NDA) progressed as planned during the quarter, and we remain fully engaged in a constructive, transparent dialogue with the agency as we approach the final month of the review.